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Soluble amyloid-b oligomers (Abo) trigger
Alzheimer’s disease (AD) pathophysiology and bind
with high affinity to cellular prion protein (PrPC). At
the postsynaptic density (PSD), extracellular Abo
bound to lipid-anchored PrPC activates intracellular
Fyn kinase to disrupt synapses. Here, we screened
transmembrane PSD proteins heterologously for
the ability to couple Abo-PrPC with Fyn. Only coex-
pression of the metabotropic glutamate receptor,
mGluR5, allowed PrPC-bound Abo to activate Fyn.
PrPC and mGluR5 interact physically, and cyto-
plasmic Fyn forms a complex with mGluR5.
Abo-PrPC generates mGluR5-mediated increases of
intracellular calcium in Xenopus oocytes and in neu-
rons, and the latter is also driven by human AD brain
extracts. In addition, signaling by Abo-PrPC-mGluR5
complexesmediates eEF2 phosphorylation and den-
dritic spine loss. For mice expressing familial AD
transgenes, mGluR5 antagonism reverses deficits
in learning, memory, and synapse density. Thus,
Abo-PrPC complexes at the neuronal surface acti-
vate mGluR5 to disrupt neuronal function.
INTRODUCTION
Alzheimer’s disease (AD) has a distinct pathology with plaques of
amyloid-b (Ab) and tangles of hyperphosphorylated tau. Rare
autosomal dominant AD cases with mutations of amyloid-b pre-
cursor protein (APP) or presenilin (PS1 or PS2) provide proof that
Ab pathways can trigger AD (reviewed in Holtzman et al., 2011).
Other APP mutations reduce AD risk (Jonsson et al., 2012).
Biomarker studies of late onset AD have shown that Ab dysregu-
lation, detected by CSF levels or by PET, is the earliest detect-
able change, consistent with Ab as a trigger (Holtzman et al.,
2011).The mechanism whereby Ab leads to AD is less clear. Atten-
tion has focused on soluble oligomers of Ab (Abo) as causing
synaptic malfunction and loss of dendritic spines (Shankar
et al., 2008). In the only reported genome-wide unbiased screen
for Abo binding sites, we identified PrPC (Laure´n et al., 2009). Ab
binding to PrPC is high affinity and oligomer-specific (Chen et al.,
2010; Laure´n et al., 2009). In vivo, PrPC is not essential for certain
Ab-related phenotypes, but is required for cell death in vitro, for
reduced survival of APP/PS1 transgenic lines, for epileptiform
discharges, for synapse loss, for serotonin axon degeneration,
and for spatial learning and memory deficits (reviewed in Um
and Strittmatter, 2013). Critically, the ability of human AD
brain-derived Ab species to suppress synaptic plasticity requires
PrPC, and human AD brain contains PrPC-interacting Abo and
Ab-PrPC complexes (Barry et al., 2011; Freir et al., 2011; Um
et al., 2012; Zou et al., 2011).
Abo-PrPC complexes signal to intracellular Fyn kinase (Larson
et al., 2012; Um et al., 2012). PrPC phenotypes in fish and worms
require Fyn (Bizat et al., 2010; Ma´laga-Trillo et al., 2009), Fyn
regulates Glu receptor traffic and plasticity (Grant et al., 1992;
Prybylowski et al., 2005), and Fyn interacts with tau (Ittner
et al., 2010; Roberson et al., 2011). Both PrPC and Fyn are en-
riched in the postsynaptic density (PSD), and Abo engagement
of PrPC activates Fyn to phosphorylate NMDA receptors (Larson
et al., 2012; Um et al., 2012).
The connection from Abo-PrPC complexes to Fyn cannot be
direct, because PrPC is anchored via glycolipid to the plasma
membrane whereas Fyn is cytoplasmic. Because both are
enriched in PSDs (Collins et al., 2006; Um et al., 2012), we
hypothesized that a transmembrane PSD protein might couple
PrPC with Fyn. The PSD proteome includes 81 transmembrane
proteins (Collins et al., 2006; Emes et al., 2008). Here, we
screened PSD transmembrane proteins for their ability to couple
Abo-PrPC with Fyn. We identified mGluR5 as linking PrPC to Fyn.
Activation of neuronal Fyn requires both mGluR5 and PrPC.
Abo-PrPC can drive mGluR5-dependent calcium mobilization
and eEF2 phosphorylation. Antagonists of mGluR5 prevent
Abo-induced dendritic spine loss and AD transgene learning
andmemory deficits. These studies define an Abo-PrPC-mGluR5
complex that leads to impaired neuronal function.Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc. 887
Figure 1. Metabotropic GluR5 Links Abo/PrPC Complexes to Fyn
(A) Schematic indicating that Abo/PrPC complexes require a coreceptor to activate Fyn in PSDs.
(B) Pie charts show transmembrane proteins (81) among total PSD proteins (651). Transmembrane proteins were subdivided; those that were screened in
Abo/Fyn assays (56, yellow) and those not (25, gray).
(C) Immunoblot of screening for Fyn activation. HEK293T cells were transfected with expression vectors for Fyn, PrPC, or candidate genes. After treatment with
1 mM Abo for 15 min, lysates were analyzed by anti-phospho-SFK (Tyr416) or anti-Fyn immunoblot.
(D) The ratio of phospho-SFK to Fyn is plotted from three experiments with Abo. Blue line indicates themean of all controls. Dark gray is 1 SD, and light gray is 2 SD
from control.
(legend continued on next page)
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Screen for PSD Proteins Mediating Abo/PrPC Signaling
Identifies mGluR5
We considered the 81 known transmembrane PSD proteins as
potential mediators (Figures 1A and 1B). We utilized a cell type
in which PrPC and Fyn fail to couple. When PrPC and Fyn are
overexpressed in HEK293T cells, Abo does not activate Fyn,
as in neurons (Um et al., 2012). We coexpressed PSD proteins
together with PrPC and exposed the HEK cells to Abo prior to
assessing Fyn activation by anti-phospho-SFK (Src family
kinase) immunoblot (Figures 1B–1D). In addition to 56 docu-
mented PSD proteins, we included APLP1 and APLP2, due
similarity with the PSD protein, APP, and known interaction
with PrPC or Abo (Bai et al., 2008; Laure´n et al., 2009; Schmitt-
Ulms et al., 2004). We included the LRRTM family because
they organize synapses and modify Ab levels (Linhoff et al.,
2009; Majercak et al., 2006). Of 61 proteins screened, only
mGluR1 andmGluR5 increased Fyn activation by >2 SD (Figures
1C and 1D). mGluR5 is reported to coimmunoprecipitate and
activate Fyn (Heidinger et al., 2002), to redistribute after Abo
(Renner et al., 2010), to colocalize with Abo (Renner et al.,
2010), and to be required for Abo suppression of LTP (Rammes
et al., 2011; Shankar et al., 2008; Wang et al., 2004).
In the initial screen with Abo, mGluR1 or mGluR5 activity might
have been ligand-dependent or independent. Although coex-
pression of either receptor results in baseline activation of Fyn,
only mGluR5 mediates Abo activation (Figures 1E–1G). Abo-
induced Fyn activation in transfected HEK cells is PrPC depen-
dent, as shown previously for neurons (Um et al., 2012), because
when mGluR5 is expressed without PrPC, no Abo regulation of
Fyn occurs. In contrast, basal Fyn activity (without Abo) is inde-
pendent of PrPC and equal for mGluR1 and mGluR5. Thus,
mGluR5 alone has the property of mediating Abo-PrPC activation
of Fyn in HEK cells.
Although EphB2 is not a PSD consensus member, we consid-
ered EphB2 as a link between Abo and Fyn because it couples
with Fyn during development, and because Ab alters EphB2 level
(Cisse´ et al., 2011; Takasu et al., 2002). In HEK, coexpression of
EphB2 and Fyn yields kinase activation (Takasu et al., 2002), but
EphB2 does not mediate Abo signaling (Figure S1 available
online).
We sought to determine whether neuronal mGluR5 is required
for Abo-induced Fyn activation. The mGluR5 negative allosteric
modulator, MPEP, blocks Abo-induced Fyn activation in HEK(E) HEK293T cells were transfected with vectors for Fyn, PrPC, or mGluR5, and tre
with 100 mMMPEP prior to Ab. Lysates were analyzed by anti-phospho-SFK (Tyr
(F) HEK293T cells were transfected with vectors for Fyn, PrPC, or Myc-mGluR1
analyzed by anti-phospho-SFK (Tyr416), anti-Fyn, anti-Myc, or anti-PrPC immun
(G) Quantification of phospho-SFK level in lysates from (E) and (F) normalized to F
hoc pairwise comparisons.
(H) Cortical neurons from E17 WT mice at 21 DIV were treated with 0 or 1 mM of
MPMQ for 30 min prior to Abo. Lysates were subjected to immunoblot with anti-
(I) Cortical neurons fromWT orGrm5/mice after 21 DIV were treated with 0 or 1
Fyn, or anti-mGluR5 immunoblot. Actin is loading control.
(J) Quantification of phospho-SFK level in lysates from (H) and (I) normalized to Fy
hoc pairwise comparisons.
See also Figure S1.cells (Figure 1E), so we preincubated cortical neurons with
MPEP, or the related MTEP, prior to Abo (Figures 1H and 1J).
Neither MTEP nor MPEP alters baseline Fyn activity, but both
eliminate Abo-induced activation. The mGluR1 antagonist,
MPMQ, does not prevent Abo-induced Fyn activation (Figures
1H and 1J). We also cultured Grm5/ cortical neurons and
exposed them to Abo at 21DIV (Figures 1I and 1J). Under basal
conditions, phospho-Fyn levels were similar to wild-type (WT),
but the increase by Abo was eliminated. Thus, mGluR5, as well
as PrPC, is required for this Abo signal transduction.
mGluR5 Does Not Bind Abo but Physically Associates
with PrPC and Fyn
With evidence that PrPC, mGluR5, and Fyn participate in Abo
signaling, we assessed physical interaction among them. We
visualized Abo binding to COS-7 cells expressing mGluR5,
PrPC, both, or neither (Figures 2A and 2B). Abo binding to
PrPC-expressing cells is not altered by mGluR5, and there is
no detectable binding of Abo to mGluR5 without PrPC. PrPC
alone accounts for Abo surface binding.
If mGluR5 serves as a bridge between PrPC and Fyn, then it is
predicted to interact physically with both. We confirmed an
association of mGluR5 with Fyn (Heidinger et al., 2002), and
observed no alteration by PrPC or Abo (Figure S2A). Both
mGluR1 and mGluR5 associate with Fyn, but mGluR8 does not
(Figure S2B). In HEK293T cells, PrPC immunoprecipitates
contain mGluR5, regardless of Abo (Figure 2C). Both mGluR1
and mGluR5, but not mGluR8, coimmunoprecipitate with PrPC
(Figure 2D). We utilized this specificity to examine whether
discrete mGluR5 domains are responsible for PrPC interaction
(Figure S2C). Chimeric proteins containing the N-terminal glob-
ular domain from one mGluR fused to the transmembrane
domains from another mGluR were coexpressed with PrPC.
Each chimera coimmunoprecipitates PrPC less effectively than
mGluR5 (Figure S2D), suggesting that the PrPC-interacting re-
gions are distributed in the protein.
In brain, mGluR5 and PrPC are coenriched in detergent-resis-
tant PSD fractions (Figure 2E) (Collins et al., 2006; Um et al.,
2012). To assess association of endogenous proteins extract-
able with nondenaturing detergent, we covalently crosslinked
proteins and then precipitated PrPC. The PrPC immunoprecipi-
tates contain mGluR5, but not mGluR8, NR2B, or GluR1 (Fig-
ure 2F). Immunoprecipitates from Prnp/ samples do not
exhibit mGluR5. Thus, Abo-PrPC, PrPC-mGluR5, and mGluR5-
Fyn pairwise physical associations are detectable.ated with 0 or 1 mMAbo for 15min. Some cultures were preincubated for 30min
416), anti-Fyn, anti-mGluR5, or anti-PrPC immunoblot. Actin is loading control.
as indicated. After cell treatment with 0 or 1 mM Abo for 15 min, lysates were
oblot. Actin is loading control.
yn. Mean ± SEM, n = 4 experiments. **p < 0.01; *p < 0.05; ANOVA, Tukey post
Abo for 15 min. Indicated samples were treated with 100 mM MTEP or 10 mM
Fyn, or anti-phospho-SFK (Tyr416). Actin is loading control.
mMAbo for 15min. Lysates were analyzed by anti-phospho-SFK (Tyr416), anti-
n. Mean ± SEM, n = 3 experiments. ***p < 0.001; *p < 0.05; ANOVA, Tukey post
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Figure 2. PrPC Interacts with mGluR5
(A) Abo (250 nM) binding to COS7 cells expressing mGluR5, PrPC, or coexpressing mGluR5 with PrPC (top). Protein expression was confirmed by immunoflu-
orescence (bottom). Scale bar represents 50 mm.
(B) Dose response for Abo binding to COS7 cells from experiments as in (A). Mean ± SEM, n = 3 experiments.
(C) HEK293T cells were transfected with vector for either mGluR5 or PrPC, or cotransfected for mGluR5 and PrPC. After treatment with 0 or 1 mM Abo for 1 hr,
lysates (input) and anti-PrPC immunoprecipitates were immunoblotted with either anti-mGluR5 or anti-PrPC.
(D) HEK293T cells were transfected with vector for PrPC or cotransfected with different Myc-taggedmGluRs and PrPC, as indicated. Lysates (input) and anti-Myc
immunoprecipitates were immunoblotted with either anti-Myc or anti-PrPC antibodies.
(E) Indicated fractions (20 mg protein) were prepared and analyzed by immunoblot with anti-PrPC, anti-mGluR5, anti-EphB2, anti-PSD95, and anti-synaptophysin
antibodies.
(F) Brain lysates from WT or Prnp/ mice were crosslinked with the cleavable DTSSP. Whole lysates (5% input) and anti-PrPC immunoprecipitates were
immunoblotted with anti-mGluR5, anti-mGluR8, anti-NR2B, anti-GluR1, or anti-PrP antibodies. Asterisk, Ig light chain.
(G) His-tagged human PrPC was incubated with DIV21 WT or Grm5/ neurons for 1 hr. Neurons were then fixed and stained with human-specific anti-PrPC
antibody and Alexa-568 secondary antibody with rhodamine-phalloidin as counterstain. Scale bar represents 10 mm.
(H) Quantification of His-PrPC bound to WT or Grm5/ neurons. His-PrPC immunofluorescence was measured by ImageJ in segments of primary dendrites
10 mm from the soma and background-subtracted. Mean ± SEM, n = 3 embryos for each genotype.***p < 0.001; Student’s two-tailed t test.
See also Figure S2.
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mGluR5 Links Abo-PrPC to Intracellular SignalingTo evaluate PrPC specificity for mGluR5, we applied soluble
PrPC as a ligand to mGluR5-expressing cells. PrP-His binds
more avidly to COS-7 cells expressingmGluR5 than to nontrans-
fected or mGluR1-expressing or mGluR8-expressing cells (Fig-
ures S2E and S2F). Thus, in this more stringent test of protein
interaction, mGluR5, but not mGluR1 or mGluR8, has affinity890 Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc.for PrPC. We utilized similar conditions to examine soluble
PrPC binding to neurons with a human-specific anti-PrPC to
selectively visualize immunoreactivity of the recombinant ligand
(Figures 2G and 2H). Punctate binding of soluble PrPC along
dendrites is visible (Figure 2G). This staining is reduced by
70% in Grm5/ cultures, with the remaining signal similar to
Figure 3. Abo Directly Stimulate mGluR5
(A) Representative traces obtained from oocytes
expressing mGluR5 plus PrPC, or mGluR1 plus
PrPC. Bath application (bars) of Abo (1.5 mM
monomer equivalent, estimated 15 nM oligomer)
or Glu (100 mM) elicits an inward current from
mGluR5 plus PrPC oocyte. Exposure to Glu, but
not Abo, elicits a response in oocytes expressing
mGluR1 and PrPC.
(B and C) Quantification of the peak current eli-
cited by glutamate (B) or Abo (C) in oocytes ex-
pressing the indicated proteins, with or without
pretreatment with 5 mg/ml anti-PrPC antibody,
6D11. Data are presented as mean ± SEM, n =
8–28 oocytes. **p < 0.01; ANOVA, Tukey post hoc
pairwise comparisons.
(D) Dose response for Abo-induced current in
oocytes expressing mGluR5 and PrPC. Mean ±
SEM for n = 4–7 oocytes.
(E) Oocytes expressing mGluR5 and PrPC were
either treated for 1 min with 100 mM Glu to maxi-
mally stimulate a response 3min prior to testing for
an Abo response, or not prestimulated with Glu.
Alternatively, some oocytes were preincubated
with 100 mM BAPTA-AM for 60 min. After these
pretreatments, the peak inward current was
measured in response to 1.5 mM Abo. Mean ±
SEM, n = 6–12 oocytes. **p < 0.005; ANOVA,
Tukey post hoc pairwise comparisons.
See also Figure S4.
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mGluR5 Links Abo-PrPC to Intracellular Signalingthe nonspecific low-affinity level observed in nontransfected
COS-7 cells (Figures S2E and S2F). We conclude that mGluR5
contributes significantly as a PrPC partner on the neuronal
surface.
Expression of PrPC Plus mGluR5 Supports Abo-Induced
Increase of Intracellular Calcium
Activation of Fyn is one consequence of mGluR5 engagement,
but activation of the heterotrimeric GTPases, Gq/G11, with sub-
sequent production of inositol (3,4,5) trisphosphate (IP3) and
release of intracellular calcium, is the more prominent pathway
(Lu¨scher and Huber, 2010). We considered whether Abo-PrPC
might activate this pathway by injecting RNA for mGluR5 and
PrPC into Xenopus laevis oocytes and applying a two-electrodeNeuron 79, 887–902, Svoltage clamp during bath perfusion of
Abo. G protein activation of phospholi-
pase C leads to IP3, calcium release,
and opening of an easily detected trans-
membrane chloride channel in oocytes
(Saugstad et al., 1996; Strittmatter et al.,
1993). Glu-induced responses of 3,000
nA peak current at 60 mV are detected
in oocytes expressing mGluR1 or
mGluR5 (Figures 3A and 3B). PrPC does
not alter the Glu responses. Bath applica-
tion of Abo had no effect on conduc-
tances for uninjected oocytes, or oocytes
expressing mGluR5 alone or PrPC alone
(Figure 3C). However, in the double-expressing mGluR5-PrPC oocytes, Abo produced an inward
current of 300–450 nA, 10% of the Glu-induced current. We
included only mGluR oocyte batches with Glu responses
>500 nA. For preparations with <500 nA responses to Glu, Abo
responses of 10% Glu magnitude may be present, but are not
prominent. The kinetics and reversal potential for the Abo-
induced signal were indistinguishable from that of Glu acting
on mGluR5 alone (Figure 3A and not shown).
The specificity of the Abo-induced current of PrPC-mGluR5
oocytes was examined. Although mGluR1 expression leads to
equally strong Glu-induced current (Figures 3A and 3B), there
is no detectable Abo-induced current (Figures 3A and 3C).
PrPC lacking the Abo binding domain, PrPD23–111 (Chen
et al., 2010; Laure´n et al., 2009; Um et al., 2012), fails to supporteptember 4, 2013 ª2013 Elsevier Inc. 891
Figure 4. Ab Species from Human AD Brains or Synthetic Abo Increase Intracellular Calcium via PrP and mGluR5
(A) Change of intracellular calcium in E17 cortical neurons from WT, Prnp/, or Grm5/ mice in response to Abo, vehicle (Veh) or ionomycin (500 nM) was
monitored by FLIPR calcium assay. Mean ± SEM, n = 24–40 wells from three to five embryos per genotype.
(B) Quantification of calcium response induced by Abo or vehicle (Veh) from (A). *p < 0.05, **p < 0.01 ***p < 0.001; ANOVA, Tukey post hoc pairwise comparisons.
(C) Quantification of calcium response induced by oligomeric Ab (Abo), monomeric Ab (Abm), or vehicle (Veh). ***p < 0.001; ANOVA, Tukey post hoc pairwise
comparisons.
(D) Intracellular calcium in E17 cortical neurons in response to human AD brain extracts (AD), n = 25, age-matched control brain (Con), n = 19 (1.5 mg total protein/
ml) or ionomycin (500 nM) monitored by FLIPR calcium assay. Mean ± SEM, ***p < 0.001 by repeated-measures ANOVA for 10 s window after AD brain extract.
(E) Quantification of calcium response induced by AD or Con extracts from (C). Each dot is from a different brain. ***p < 0.001 by Student’s two-tailed t test.
(legend continued on next page)
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mGluR5 Links Abo-PrPC to Intracellular SignalingAbo-induced signaling through mGluR5 (Figure 3C). The anti-
PrPC antibody, 6D11, binds to residues 95–105 and prevents
Abo interaction (Chung et al., 2010; Laure´n et al., 2009; Um
et al., 2012). Preincubation with 6D11 blocks Abo responses,
but not Glu responses, in PrPC-mGluR5 oocytes (Figures 3B
and 3C). The Abo-induced response has an EC50 of 1 mMmono-
mer equivalent, an estimated 10 nM oligomer concentration (Fig-
ure 3D). A characteristic of G protein-mediated responses in
Xenopus oocytes is strong desensitization. Maximal Glu stimula-
tion nearly eliminates subsequent responses to Glu for 10–
15 min. Consistent with the Abo-PrPC-mGluR5 responses
sharing this pathway, pretreatment with Glu eliminates the
response to subsequent Abo (Figure 3E). In addition, pretreat-
ment with cell permeable BAPTA-AM to chelate intracellular cal-
cium abrogated the Abo-induced signal (Figure 3E), as for Glu
(Saugstad et al., 1996). Thus, Abo interaction with a PrPC-
mGluR5 complex mobilizes calcium stores. Although mGluR5-
mediated signaling to Fyn is as robust with Abo-PrPC as with
Glu, signaling to calcium mobilization is substantially less effec-
tive for Abo-PrPC than with Glu as the mGluR5 ligand, so Abo
does not mimic Glu precisely.
Acute Abo-Induced Calcium Signals in Neuronal Culture
Require mGluR5 and PrPC
We considered whether Abo regulates neuronal calcium
signaling through mGluR5 directly and acutely. Chronic Abo-
PrPC-Fyn signaling can indirectly alter NMDA receptor (NMDAR)
trafficking to modulate NMDA-induced calcium responses (Um
et al., 2012). We used a calcium-sensitive fluorescent dye to
assess direct immediate response to Abo in 21 days in vitro
(DIV) cortical cultures. In low-density cultures, there is little direct
calcium response to Abo under the conditions that modulate
NMDAR responses (data not shown; Um et al., 2012). With
microscopic imaging, Abo occasionally induces local calcium
transients, but there is no generalization and measurement
across a microtiter well does not detect a change (not shown).
Higher density cultures exhibit spontaneous synchronized cal-
cium increases (Figure S3A) that depend on network connectiv-
ity being suppressed by tetrodotoxin (TTX), 6-cyano-7-nitroqui-
noxaline-2,3-dione (CNQX), or 2-amino-5-phosphonopentanoic
acid (APV) (Figures S3B and S3C) (Dravid and Murray, 2004).
Under these conditions, Abo induces an increase of intracellular
calcium (Figure 4A). Averaging multiple wells smoothes random
spontaneous signals (Figure S3A), and Abo-induced responses(F) Correlation between AD extract-induced calcium and PrP(23–111)-interactin
coefficient of linear correlation reported with two-tailed p.
(G) Calcium response induced by AD extracts preabsorbedwith Fc (AD Fc) or PrPC
resin (Con PrP-Fc). *p < 0.05, **p < 0.01; ANOVA, Tukey post hoc pairwise comp
(H) Calcium response induced by AD or Con extracts in E17 cortical neurons from
each genotype. *p < 0.05, **p < 0.01; ANOVA, Tukey post hoc comparisons.
(I) Calcium response induced by AD or Con extracts in WT cortical neurons. Neuro
saracatinib for 1 hr or 100 nM thapsigargin for 24 hr prior to AD extract. *p < 0.05
extract only samples.
(J) WT cortical neurons were treated with 0 or 1 mM Abo for 15 min. Indicated sam
analyzed by anti-phospho-SFK or anti-Fyn immunoblot.
(K) Quantification of phospho-SFK level in the lysate normalized to Fyn from thr
pairwise comparisons.
See also Figure S3.are apparent (Figure 4A). This response is oligomer specific; no
response is detected with monomeric Ab (Figure 4C). In either
Grm5/ or Prnp/ neurons, the spontaneous synchronized
calcium signals are indistinguishable from WT (Figures S3D
and S3E). However, Abo fails to induce a calcium signal in net-
works lacking either PrPC or mGluR5 (Figure 4B).
To assess whether similar responses occur with human
autopsy tissue, we utilized Tris-buffered saline (TBS)-soluble ex-
tracts from human brain, which we have previously character-
ized for PrPC-interacting Ab species and for Fyn activation in
mouse cultures (Table S1) (Um et al., 2012). In high-density
cortical cultures, dialyzed TBS-soluble brain extracts from AD
cases generate greater calcium mobilization than do control
brain extracts (Figures 4D and 4E; p < 0.001). Moreover, the level
of PrP(23–111)-interacting Ab in human brain samples correlates
with the magnitude of the calcium response (Figure 4F). Preab-
sorption with anti-Ab antibody removes PrPC-interacting Ab
immunoreactivity (Figure S3H) and reduces the calcium
response (Figures S3F and S3G). Preabsorption with PrP-Fc,
but not control Fc resin, removes PrPC-interacting species and
reduces the calcium response (Figures 4G and S3I). Thus,
PrPC-interacting Ab species in human AD brain TBS-soluble ex-
tracts stimulate calcium signals in high-density neuronal cul-
tures. These responses require network connectivity, and are
blocked by TTX, CNQX, or APV (Figure S4J). The mGluR5 antag-
onists, MPEP and MTEP, block the AD brain extract response
(Figure 4I). In contrast, the mGluR1 antagonist MPMQ does not
block the AD extract-induced response (Figure 4I). Furthermore,
the ability of human AD brain extract to induce a calcium signal is
eliminated in Grm5/ or Prnp/ neurons (Figure 4H).
We considered the source of calcium for the AD extract-
induced signal and its relationship to Fyn. Thapsigargin (TG) pre-
treatment prevented signaling, consistent with release from
endoplasmic reticulum stores (Figure 4I). In contrast, TG pre-
treatment did not prevent Fyn activation (Figures 4J and 4K),
and inhibition of Fyn with saracatinib did not prevent calcium
signaling (Figure 4I). Although Fyn and calcium signaling by AD
extracts require both PrPC and mGluR5, the two mediators
appear pharmacologically separable.
Chronic Abo has the potential to desensitize mGluR5 calcium
responses. We assessed this in two models: HEK293 cells ex-
pressing mGluR5 and PrPC, and low density cultured neurons.
HEK-mGluR5 cells respond to Glu with calcium elevation and
there is no effect of Abo preincubation (Figures S4A, S4B, andg Ab species is plotted. Each point is from a different brain sample. Pearson
-Fc resin (ADPrP-Fc), or Con extracts preabsorbedwith Fc (Con Fc) or PrPC-Fc
arisons.
WT, Prnp/ or Grm5/mice. Mean ± SEM, n = 3 independent embryos for
ns were pretreated with 100 mMMPEP, 100 mMMTEP, 10 mMMPMQ, 500 nM
, **p < 0.01, ***p < 0.001; ANOVA, Tukey post hoc pairwise comparisons to AD
ple was treated with 100 nM thapsigargin for 24 hr prior to Abo. Lysates were
ee experiments. Mean ± SEM, *p < 0.05; **p < 0.01; ANOVA, Tukey post hoc
Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc. 893
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mGluR5 Links Abo-PrPC to Intracellular SignalingS4F). For HEK cells stably expressing mGluR5 and PrPC, base-
line Glu responses are similar, but Abo preincubation sup-
presses Glu responses by 50% in independent clones (Figures
S4A, S4C, S4D, and S4F). This effect requires the Abo-binding
PrP(23–111) domain because clones expressing a truncation
mutant fail to bind Abo (Figure S5A), and show no Abo suppres-
sion of Glu-induced calcium (Figures S4E and S4F). Abo-
induced suppression of mGluR5 responses is also observed in
neurons. In low density cultures, there are no spontaneous
synchronized calcium oscillations, but the mGluR5 agonist, (S)-
3,5-dihydroxyphenylglycine (DHPG), results in synchronized
oscillations (Figure S4G). Pretreatment with Abo nearly elimi-
nates DHPG-induced oscillations in WT neurons (90% inhibition;
Figures S4H and S4I). The Abo suppression of DHPG-induced
oscillations is limited to 40% in Prnp/ cultures (Figure S4I).
Multiple mechanisms contribute to mGluR5 desensitization,
including protein kinase C, calcium/calmodulin binding, and re-
ceptor internalization. We assessed the effect of Abo and the
group I mGlu receptor agonist, DHPG, on cell surface mGluR5
levels using biotinylation of live neurons with a cell impermeable
reagent (Figures S4J–S4L). At 1 hr, DHPG reduces surface
mGluR5 by 20%, as described (Choi et al., 2011). In contrast,
Abo treatment generates a PrPC-dependent 25% increase in
surface/total mGluR5 ratios (Figures S4J–S4L). The increase
after Abo addition may reflect ‘‘trapping’’ of mGluR5 in relatively
immobile complexes (Renner et al., 2010). Despite this differ-
ence between Abo and DHPG in mGluR5 trafficking, Abo treat-
ment suppresses mGluR5 signaling (Figures S4H and S4I).
Abo Signals through PrPC and mGluR5 to Protein
Translation Machinery
Metabotropic GluRs have effects on protein translation (Lu¨scher
and Huber, 2010), as well as calcium release and Fyn. We exam-
ined whether Abo-PrPC-mGluR5 coupling might alter phosphor-
ylation of eukaryotic elongation factor 2 (eEF2). The mGluR5
agonist, DHPG, drives eEF2-56T phosphorylation (Figure S5A).
Abo treatment has a similar effect on eEF2 phosphorylation (Fig-
ures 5A, 5B, and S5A–S5C). Mediation of the Abo effect by
mGluR5 is demonstrated by inhibition with MTEP (Figures S5B
and S5C). In contrast, the mGluR1 antagonist, MPMQ, does
not prevent Abo-induced eEF2 phosphorylation (Figures S5D
and S5E). Genetic analysis with Prnp/ and Grm5/ neurons
confirms that the Abo effect on eEF2 phosphorylation depends
on these proteins (Figures 5A and 5B). Abo-induced eEF2 phos-
phorylation is detected in dendrites, and is absent inPrnp/ and
Grm5/ neurons (Figures 5C and 5D). The addition of both Abo
and DHPG produced no greater eEF2 phosphorylation than
either ligand alone, consistent with occlusive action (Figures
S5F and S5G).
Dendritic translation of Arc is under mGluR5 control, via an
eEF2-dependent mechanism (Park et al., 2008). As predicted
from the mGluR5-mediated action of Abo on p-eEF2, dendritic
Arc immunoreactivity is elevated after 5 min Abo exposure (Fig-
ures 5E and 5F) and Arc immunoblot signal increases in brain
slices (Figures S5H and S5I).
To extend the AD relevance of these observations, we tested
whether human AD extracts generated a similar pattern. Pooled
TBS-soluble extracts from AD brain, but not control brain,894 Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc.elevated eEF2 phosphorylation in WT mouse 21 DIV neurons
(Figures 5G and 5H). This signaling is not observed in Grm5/
and Prnp/ cultures. Thus, Abo-PrPC complexes signal through
mGluR5 to modify Fyn activation, calcium levels, and eEF2
phosphorylation.
We considered how Abo-induced eEF2 phosphorylation re-
lates to Fyn activation and calcium signaling. Saracatinib sup-
presses basal p-SFK levels and prevents Abo stimulation of
Fyn (Figure 5I) and also prevents Abo-induced eEF2 phosphory-
lation (Figures 5I and 5K). Thapsigargin pretreatment prevents
AD extract-induced calcium signaling (Figure 4H) and also pre-
vents eEF2 phosphorylation (Figures 5J and 5K). Thus, eEF2
regulation by Abo requires both Fyn and calcium signaling.
Cellular Effects of Abo Require mGluR5
Time-lapse imaging of myristoyl-GFP expressing neurons (Fig-
ure 6A) has shown that Abo leads to a loss of 10% of dendritic
spines over 5 hr by a Prnp- and Fyn-dependent mechanism
(Um et al., 2012). Acute DHPG treatment leads to immature
spines, reduced spine volume, and fewer surface AMPA recep-
tors during chemical long-term depression (LTD) (Abu-Elneel
et al., 2008; Moult et al., 2006; Vanderklish and Edelman,
2002), whereas chronic DHPG results in decreased spine
density (Shinoda et al., 2010). We tested whether mGluR5
blockade prevents Abo-induced spine loss. MPEP treatment
does not alter baseline spine stability over 5 hr, but prevents
Abo-induced loss (Figures 6A and 6B). Deletion of mGluR5
also prevents Abo-induced spine loss (Figures 6A and 6C).
Thus, mGluR5 participates in morphological effects of Abo-
PrPC complexes.
The Abo-PrPC-Fyn pathway contributes to short-term lactate
dehydrogenase (LDH) release from neurons (Um et al., 2012).
Either addition of the mGluR5 negative allosteric modulator,
MTEP, or deletion of the Grm5 gene prevents Abo-induced
LDH release (Figures 6D and 6E).
mGluR5 Antagonist Reverses Behavioral Deficits in FAD
Transgenic Mice
The double transgenic APPswe/PS1DE9 (APP/PS1) mouse
exhibits normal behavior through age 6 months, and then
progressively loses learning and memory (Gimbel et al., 2010;
Jankowsky et al., 2003). We considered a role for mGluR5. As
reported (Lu et al., 1997; Xu et al., 2009), constitutive mGluR5
deletion impairs performance (Figure S6). Treatment of WT
mice with high dose MTEP, 40 mg/kg, impairs alertness and
electroencephalogram (EEG) amplitude (Figure S6). Thus, we
sought to achieve partial inhibition of mGluR5 with 15 mg/kg
MTEP, which does not alter EEG rhythm (Figure S6).
First, we treated WT and APP/PS1 mice with vehicle or MTEP
and assessed spatial learning in the radial arm water maze
(Figure 7A). Mice at 9 months age were randomized to blinded
treatment with vehicle or MTEP (15 mg/kg, two times a day for
10 days) for 3 days prior to, and then for 7 days throughout
memory testing. Learning is impaired in transgenics relative to
WT, but is fully recovered with MTEP. There is a significant
interaction of genotype and drug (two-way repeated-measures
[RM] ANOVA: APP/PS1 3 MTEP interaction, p < 0.01; APP/
PS1, p < 0.01; MTEP, p < 0.01).
Figure 5. eEF2 Phosphorylation Is
Enhanced by Abo through PrP and mGluR5
(A) DIV21 cortical neurons from WT, Prnp/, or
Grm5/mice were treated with 0 or 1 mM Abo for
5 min. Lysates were analyzed by anti-phospho-
eEF2, or anti-eEF2 immunoblot. GAPDH is loading
control.
(B) Phospho-eEF2 level in the lysate normalized to
eEF2. WT, n = 3; Prnp/, n = 3; Grm5/, n = 3.
Mean ± SEM, **p < 0.01; Student’s two-tailed
t test.
(C) Immunohistology of DIV21 WT, Prnp/, or
Grm5/ cortical neurons stained with anti-
phospho-eEF2 and anti-MAP2 antibodies after
exposure of 0 or 1 mM Abo. Scale bar represents
10 mm.
(D) Phospoho-eEF2 intensity normalized to MAP2
signal. WT, n = 3; Prnp/, n = 3; Grm5/, n = 3.
Eight to ten images were analyzed per experiment.
Mean ± SEM, ***p < 0.001; Student’s two-tailed
t test.
(E) Immunohistology of DIV 21WT neurons stained
with anti-Arc antibody after 1 mM Abo for 5 min.
Scale bar represents 5 mm.
(F) Arc intensity in dendrites after 1 mM Abo or
100 mM DHPG for 5 min. For dendritic Arc levels,
average pixel intensity was measured in second-
ary dendrites 10 mm from first branch point. WT,
n = 6. Mean ± SEM, **p < 0.01, *p < 0.05; ANOVA,
Tukey post hoc pairwise comparisons.
(G) DIV21 cortical neurons from WT, Grm5/, or
Prnp/ mice were treated with human control or
AD brain extracts (30 mg total protein/ml) for 5 min.
Lysates were analyzed by anti-phospho-eEF2 or
anti-eEF2 immunoblot.
(H) Phospho-eEF2 level normalized to eEF2 from
(G). WT, n = 6; Grm5/, n = 4; Prnp/, n = 3.
Mean ± SEM, *p < 0.05; **p < 0.01; ***p < 0.001;
ANOVA, Tukey post hoc pairwise comparisons.
(I and J) WT cortical neurons were treated with
0 or 1 mM Abo for 15 min. Indicated samples were
treated with 500 nM saracatinib for 1 hr (I) or
100 nM thapsigargin (TG) for 24 hr (J) prior to Abo.
Lysates were analyzed by anti-phospho-SFK,
anti-Fyn, anti-phospho-eEF2, or anti-eEF2 immu-
noblot. GAPDH is loading control.
(K) Phospho-eEF2 level normalized to eEF2 from
three experiments. Mean ± SEM, *p < 0.05;
ANOVA, Tukey post hoc pairwise comparisons.
See also Figure S5.
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additional cohorts. Without MTEP treatment, APP/PS1 mice at
9 months age are unable to distinguish novel and familiar
objects, whereas WT mice exhibit novel object preference (Fig-
ure 7B; p < 0.001 for WT). Exploration of two novel objects is
not different between genotypes during acclimation (not shown).
MTEP-treated APP/PS1 mice recover a novel object preference
(Figure 7B; p < 0.001 for both WT and APP/PS1 with MTEP).
A separate cohort of APP/PS1 was tested in the Morris water
maze. Without treatment, the APP/PS1 mice show greater
latencies to locate a hidden platform relative to WT across
learning trials (Figure 7C; RM-ANOVA, p < 0.001), and spend
less time in the target quadrant during a probe trial for memory24 hr later (Figure 7D; ANOVA p < 0.001). In contrast, MTEP-
treated APP/PS1 mice are indistinguishable from untreated
WT or MTEP-treated WT mice in learning and memory (Figures
7C and 7D), but are different from untreated APP/PS1 (Figures
7C and 7D; p < 0.001). There is a significant interaction of
genotype and drug (two-way RM-ANOVA in Figure 7C for APP/
PS1 3 MTEP interaction, p < 0.001; two-way ANOVA in Fig-
ure 7D, p < 0.001).
We also administered MTEP to 3XTg mice expressing mutant
APP, PS1, and Tau (Oddo et al., 2003). At 8–9 months, these
mice perform normally in the Morris water maze (not shown),
but are impaired in novel object recognition (Figure 7E). After
randomization toMTEP or vehicle, the 3XTgmice were assessedNeuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc. 895
Figure 6. Abo-Induced Toxicity Is Blocked
by mGluR5 Antagonists
(A) Hippocampal neurons (21 DIV) expressing
myristoyl-GFP from WT or Grm5/ mice were
imaged for 6 hr with or without MPEP (100 mM).
Abo (500 nM monomer equivalent) or vehicle
was added at 1 hr. Note loss of several spines after
Abo addition in the WT neurons. Scale bar repre-
sents 1 mm.
(B and C) Dendritic spine loss over 5 hr is plotted
as a function of Abo and MPEP (B) or Grm5
genotype (C). Mean ± SEM, n = 3–5 cultures
from separate mice of each genotype. *p < 0.05;
**p < 0.01; ANOVA, Tukey post hoc pairwise
comparisons.
(D) Neurons at DIV21 from WT mice were treated
with 0 or 1 mM Abo for 2 hr. Some cultures were
treated with 100 mM MTEP for 1 hr prior to Abo.
Cell toxicity was determined by LDH release.
Mean ± SEM, n = 3 experiments. ***p < 0.001;
ANOVA, Tukey post hoc pairwise comparisons.
(E) WT or Grm5/ cortical neurons were treated
with 0 or 1 mM Abo for 2 hr. Toxicity was deter-
mined by LDH release. Mean ± SEM, n = 4 ex-
periments. **p < 0.01; ANOVA, Tukey post hoc
pairwise comparisons.
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mGluR5 Links Abo-PrPC to Intracellular Signalingfor novel object recognition (Figure 7G). MTEP-treated 3XTg
mice show a novel object preference (p < 0.01), but vehicle-
treated mice do not. Thus, MTEP reverses memory deficits in
two transgenic AD mice.
We considered whether improved memory with MTEP is
correlated with a reversal of synaptic loss. A separate cohort of896 Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc.WT and APP/PS1 transgenic mice at
10 months age were treated for 10 days
with MTEP, 15 mg/kg two times a day.
As expected, control APP/PS1 mice
exhibit a 25%–30% decrease in area
occupied by presynaptic synaptophysin
and postsynaptic PSD-95 immunoreac-
tivity in the dentate gyrus (Figures 8A–
8C). The loss of stained synaptic area
was fully rescued by a 10-day course of
MTEP (Figures 8D and 8E). For WT
mice, MTEP did not alter synaptic den-
sity. We also assessed synaptic density
ultrastructurally, identifying synaptic pro-
files by the presence of a postsynaptic
density and presynaptic vesicles (Fig-
ure 8F). Synapse density in transgenic
dentate gyrus increased by 20% with
MTEP treatment (Figure 8G).
DISCUSSION
This study delineates a direct role for
mGluR5 in Abo-related pathophysiology.
Of transmembrane PSD proteins, only
mGluR5 supports coupling of Abo-PrPCto Fyn activation. Intracellular calcium and protein translation
are also linked to Abo-PrPC engagement viamGluR5. AnmGluR5
dependence of signaling is observed for TBS-soluble extracts of
AD brain as well as synthetic Abo, emphasizing the disease rele-
vance. A coreceptor role for mGluR5 is required for dendritic
spine loss and transgenic memory impairment. Together, these
Figure 7. mGluR5 Antagonist Reverses
Learning and Memory Deficits in AD Mouse
Models
(A) Spatial learning is plotted as the number of
errors in finding a hidden platform in a radial arm
water maze at age 9 months. Mean ± SEM for
vehicle-treated C57BL/6, n = 11; MTEP-treated
C57BL/6, n = 12; vehicle-treated APP/PS1, n = 10;
MTEP-treated APP/PS1, n = 10. Performance
differed across the last 15 swims by genotype and
treatment (two-way RM-ANOVA APP/PS1, p <
0.001; MTEP, p < 0.001). There was an interaction
between genotype and treatment (two-way
RM-ANOVA APP/PS1 3 MTEP p < 0.001). By
Tukey post hoc pairwise comparisons across
trials, the vehicle-treated APP/PS1 group differed
from each of the other groups (p < 0.001), whereas
none of the other groups differed from each other
(p > 0.05). For indicated trial blocks, the vehicle-
treated APP/PS1 group differed from each of the
other groups (*p < 0.05; **p < 0.01; ***p < 0.001),
whereas none of the other groups differed from
each other (p > 0.05).
(B) Time spent with a novel object for the same
mice as (A): vehicle C57BL/6, n = 11; MTEP
C57BL/6, n = 12; vehicle APP/PS1, n = 9; MTEP
APP/PS1, n = 9. After being acclimated to an
object, vehicle APP/PS1 mice showed no prefer-
ence for a novel object (two-tailed Student’s t test
p > 0.05). The other three groups showed prefer-
ence for a novel object (two-tailed Student’s t test
p < 0.001).
(C) Spatial learning is plotted as latency to find a
hidden platform in a Morris water maze at age
9 months in a cohort different from (A). Mean ±
SEM for untreated (naive) C57BL/6, n = 32; MTEP-
treated C57BL/6, n = 13; untreated APP/PS1, n =
38; MTEP-treated APP/PS1, n = 17. Performance
differed across the last 16 swims by genotype and
treatment (two-way RM-ANOVA for APP/PS1, p <
0.001; for MTEP, p < 0.001). There was an inter-
action between genotype and treatment (two-way
RM-ANOVA, APP/PS1 3 MTEP p < 0.001). By
Tukey post hoc pairwise comparisons across
trials, the vehicle-treated APP/PS1 group differed
from each of the other groups (***p < 0.001), whereas none of the other groups differed from each other (p > 0.05). For specific trial blocks, the untreated APP/PS1
group differed from each of the other groups (*p < 0.05; ***p < 0.001), whereas none of the other groups differed from each other (p > 0.05).
(D) Performance during a 60 s probe trial, 24 hr after learning, where time spent in the target quadrant wasmeasured. Random chance is 25%.Mean ± SEM for the
groups in (C). Target quadrant time differed by genotype and treatment (two-way ANOVA APP/PS1, p < 0.001; MTEP, p < 0.01). There was an interaction between
genotype and treatment (ANOVA, APP/PS13MTEP p < 0.001). By Tukey post hoc, the untreated APP/PS1 group differed from others (p < 0.001), whereas none
of the other groups differed from each other (p > 0.05).
(E) WT and 3XTgmice of the same genetic background at 8–9 months of age were tested for novel object recognition. WTmice show preference the novel object
(two-tailed Student’s t test p < 0.05), but 3XTg mice show no preference (p > 0.05). Mean ± SEM.
(F) The effect of MTEP administration on object recognition is tested in 3XTgmice at age 8months. Mean ± SEM for vehicle 3XTg, n = 12; MTEP 3XTg, n = 8. Mice
that receivedMTEP had a significant preference for the novel object (two-tailed Student’s t test p < 0.01) whereas vehicle 3XTgmice showed no preference (two-
tailed Student’s t test p > 0.05).
See also Figure S6.
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mGluR5 Links Abo-PrPC to Intracellular Signalingfindings delineate mGluR5 activation as a critical step in Abo
signal transduction with potential for therapeutic intervention.
Dysregulation of mGluR5 Signaling in AD
Several previous studies have indirectly implicatedmGluR5 inAbo
signaling and in AD. Abo altersmGluR5 trafficking in neurons, with
reduced diffusion, clustering, aberrant activation, and neurotox-icity (Renner et al., 2010). The results here provide a PrPC-based
mechanism for these findings and for downstream signaling.
Direct coupling of PrPC tomGluR5 has been reported for an unre-
lated ligand, the laminin gamma-1 chain (Beraldo et al., 2011). Abo
from synthetic, cellular, and human AD brain sources suppresses
LTP and enhances LTD. These actions are mimicked by mGluR5
agonists and inhibited by mGluR5 antagonists (Rammes et al.,Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc. 897
Figure 8. Synaptic Markers Recover After 10-Day Treatment With mGluR5 Antagonist
WT and APP/PS1 mice at 10 months of age were treated with 15mg/kg of MTEP, or saline, by intraperitoneal injection twice a day for 10 days and then sacrificed
for histological analysis.
(A–C) Themolecular layer of the dentate gyrus of the indicated groups was stained with anti-PSD-95 antibody and imaged with a confocal microscope and a 603
objective lens. Scale bar represents 6 mm.
(D) Fractional area of immunoreactive puncta for PSD-95 from images as in (A–C). p < 0.05, ANOVA with post hoc pairwise Fisher’s least significant difference
(LSD). Mean ± SEM, n = 5 mice per group with three images per mouse.
(E) Fractional area of immunoreactive puncta for synaptophysin. p < 0.05, ANOVA with post hoc pairwise LSD. Mean ± SEM, for n = 5 mice per group with three
images per animal.
(F) Ultrastructure of the molecular layer of the dentate gyrus from a vehicle APP/PS1 mouse. Arrows point to synapses scored in (G). Magnification is 20,5003.
Scale bar represents 1 mm.
(G) Synapses were counted in a 25 mm2 area in drug-treated and saline-treated samples. p < 0.05, two-tailed Student’s t test. Mean ± SEM, n = 5 mice per group
with 30 images per mouse.
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mGluR5 Links Abo-PrPC to Intracellular Signaling2011;Shankaretal., 2008;Wangetal., 2004). InhumanAD,mGluR
ligandbinding isdecreased inbrain relative tocontrols and the loss
is correlatedwith disease progression (Albasanz et al., 2005). Pro-
teins titratedbymGluRs, eEF-2, Arc, and p70S6kinase are dysre-
gulated in AD brain (An et al., 2003; Li et al., 2005; Wu et al., 2011).898 Neuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc.Signaling Downstream of mGluR5
Canonical mGluR5 signaling couples to Gq/G11 GTPases that
activate phospholipase C to produce IP3 and release calcium
stores (Lu¨scher and Huber, 2010). mGluR5 also modulates
plasma membrane potassium, calcium, and transient receptor
Neuron
mGluR5 Links Abo-PrPC to Intracellular Signalingpotential channels. Src family tyrosine kinases, including Fyn,
have been implicated in linking to NMDA-R (Heidinger et al.,
2002; Nicodemo et al., 2010). The proline rich tyrosine kinase 2
(Pyk2) participates in Src/Fyn interaction with mGluR signaling
(Heidinger et al., 2002; Nicodemo et al., 2010). The calcium/
calmodulin-dependent eEF2 kinase (eEF2K) is bound to mGluR5
in the basal state, but is released during activation to phosphor-
ylate eEF2 (Lu¨scher and Huber, 2010). Phospho-eEF2 reduces
global translation, but allows increased Arc/Arg3.1 expression
(Park et al., 2008). The Homer family plays a role in mGluR
signaling, interacting with receptor and eEF2K (Hu et al., 2010;
Lu¨scher and Huber, 2010; Ronesi et al., 2012). Homer interac-
tions with SHANK contribute to PSD localization, specific iso-
forms have roles in homeostatic scaling.
We show that Abo-PrPC complexes lead to several mGluR5
outputs. Fyn activation by Abo in cortical neurons requires
mGluR5 genetically and pharmacologically. Fyn is implicated in
Abo-induced dysregulation of NMDA-R trafficking and activation
(Um et al., 2012). Because Fyn binds directly to Tau (Ittner et al.,
2010; Lee et al., 2004), this may have implications for AD beyond
dysregulation of GluRs.
The Abo-PrPC-mGluR5 complex also activates phospholipase
C, as detected by monitoring calcium-activated chloride
channels in oocytes. The ability of Abo or human AD brain
TBS-soluble extract to increase calcium in cortical neurons re-
quires mGluR5 and PrPC. The calcium increase in neurons may
occur by the IP3 pathway and also by regulation of NMDA-Rs.
Fyn activation by Abo-PrPC is as strong as that by Glu, whereas
calcium mobilization appears to be an order of magnitude less
effective for Abo-PrPC than for Glu. Divergence in Abo-PrPC-
mGluR5 signaling requires further study.
Protein translation plays a major role in mGluR5 signaling
(Lu¨scher and Huber, 2010). The phosphorylation of eEF2 is
increased by Abo-PrPC as much as by mGluR5 agonist. There-
fore dysregulation of translation may contribute to synaptic
dysfunction in AD. Arc is one protein target of mGluR5 signaling
that is upregulated by Abo acutely. Calcium and Fyn are
independent mediators, which appear to cooperate in eEF2
phosphorylation.
We show thatmGluR5 antagonists prevent Abo-induced spine
loss from hippocampal neurons in vitro and in vivo. Critically,
MTEP reverses memory deficits in transgenic AD models. Multi-
ple signaling pathways from Abo-PrPC-mGluR5 complexes are
likely to participate. For spine loss in vitro, Fyn is required (Um
et al., 2012), but other mGluR5 signaling components may
contribute. Protein translation, calcium release, and Fyn kinase
are each known to participate in plasticity, learning, andmemory.
Feedback of mGluR5 Signaling on Ab Levels
The mGluR5 pathway may also feedback on APP/Ab meta-
bolism to exacerbate AD. Specifically, mGluR5 agonism ele-
vates Arc, which enhances Ab production by participating in
APP and PS1 colocalization within endocytic vesicles (Wu
et al., 2011). Shared pathways between AD and Fragile X have
been reported (Sokol et al., 2011). The FMRP protein normally
represses APP translation. Transgenicmicewith both APP trans-
genes and loss of FMRP have enhanced phenotypes, including
audiogenic seizures, which are treatable with MPEP.mGluR Specificity and Localization
Of mGluR receptors, only mGluR1 and mGluR5 interact with
Fyn and PrPC. Only mGluR5 mediates Abo-induced stimulation
of Fyn and calcium signaling in oocytes. Grm5 gene deletion
and mGluR5-specific compounds reverse Abo phenotypes,
including Fyn activation, neuronal calcium mobilization, eEF2
phosphorylation, spine loss, LDH release, and memory deficits.
The mGluR1-specific antagonist, MPMQ, does not block. Thus,
mGluR5 appears to be specifically involved in Abo-PrPC action.
PrPC, mGluR5, and Fyn have all been localized to the PSD
by subcellular fractionation. For PrPC and Fyn, high-resolution
in situ protein localization in brain has not been reported. For
mGluR5, imaging confirms a postsynaptic localization and indi-
cates that mGluR5 is dynamically located at the PSD periphery
(Lujan et al., 1996). Dynamic regulation of mGluR5 localization
by Abo has been observed (Renner et al., 2010).
Short-Term Activation versus Longer-Term
Desensitization
Although ionotropic receptors function rapidly, metabotropic re-
ceptors are slow and show prominent desensitization. Abo levels
are highly unlikely to fluctuate on the time scale of synaptic trans-
mission, so Abo-PrPC complexes may engage mGluR5 and elicit
a degree of desensitization that prevents responsiveness to
cyclic changes in Glu. Thus, mGluR5 may be dysregulated by
acute activation and chronic desensitization.
Alternate Ligands and Accessory Ectodomains for
mGluRs
Activation of mGluR5 by Abo-PrPC complexes expands the
repertoire of metabotropic glutamate receptors. Certain other
G protein coupled receptors (GPCRs) respond to more than
one ligand, and interact extracellularly with accessory subunits
or coreceptors. Melanocortin receptors recognize both melano-
cortin agonists and Agouti/AgRP antagonists with specificity
modified by MRAPs (Breit et al., 2011). Calcitonin and related
receptors have ligand preference altered by transmembrane
RAMPs (Hay et al., 2006). Noncanonical signaling by Hedgehogs
and Wnts through Smoothened and Frizzleds to heterotrimeric
G proteins depends on ligand interaction with Patched and
LRP5/6, respectively (Angers and Moon, 2009; Robbins et al.,
2012). Ectodomain accessory proteins for mGluRs have not
been recognized previously, so PrPC is unique. The only previ-
ously known endogenous ligand for mGluR5 is Glu, so the action
of Abo-PrPC is distinct from precedent. Our findings raise the
possibility that mGluR5 may be regulated physiologically by
molecules other than Glu.
Targeting mGluR5 for AD Therapy
The delineation of an Abo-PrPC-mGluR5-Fyn pathway provides
potential targets for AD intervention. Antibodies that block Abo
binding to PrPC reverse memory deficits in transgenic AD mice
(Chung et al., 2010), and we show that a mGluR5 negative allo-
steric modulator has a similar effect. However, full mGluR5
antagonism may have deleterious effects on neuronal function
and impairment of baseline attention (Lu¨scher and Huber,
2010; Simonyi et al., 2010). Deficits of contextual fear condition-
ing and inhibitory learning are observed in the absence ofNeuron 79, 887–902, September 4, 2013 ª2013 Elsevier Inc. 899
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mGluR5 Links Abo-PrPC to Intracellular SignalingmGluR5 (Xu et al., 2009), andmGluR5 function may contribute to
healthy brain aging (Lee et al., 2005; Me´nard and Quirion, 2012;
Nicolle et al., 1999). Optimal intervention may therefore be
designed to prevent Abo-PrPC activation of mGluR5, without
modifying Glu activation of mGluR5.
EXPERIMENTAL PROCEDURES
Mouse Strains
All animal studies were conducted with approval of the Yale Institutional
Animal Care andUse Committee. Themouse strains have been described pre-
viously (Gimbel et al., 2010; Jankowsky et al., 2003; Lu et al., 1997; Oddo et al.,
2003).
Cell Culture and Biochemistry
Standard procedures were utilized, including the assessment of intracellular
calcium level in neuronal culture (Um et al., 2012) and voltage clamp recording
from X. laevis oocytes (Laure´n et al., 2009; Strittmatter et al., 1993). Fresh-
frozen postmortem human prefrontal cortex from the brains of AD patients
were obtained, as approved by Institutional Review Board collected at New
York University and at Yale. Particulate components were removed from
TBS homogenates by centrifugation at 100,000 3 g for 30 min.
MTEP Treatment and Memory Testing of Transgenic Mice
Mice were randomized to treatment groups and the experimenter was
unaware of treatment status throughout behavioral testing. Procedures for
Morris water maze testing have been described (Gimbel et al., 2010).
SUPPLEMENTAL INFORMATION
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